{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:53:47Z","timestamp":1790254427497,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/000775"],"award-info":[{"award-number":["PI18\/000775"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC18\/00072"],"award-info":[{"award-number":["AC18\/00072"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\u201cla Caixa\u201d Foundation","doi-asserted-by":"publisher","award":["3922-19 FCRB"],"award-info":[{"award-number":["3922-19 FCRB"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.573179","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T06:21:27Z","timestamp":1602742887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Manufacturing and Management of CAR T-Cell Therapy in \u201cCOVID-19\u2019s Time\u201d: Central Versus Point of Care Proposals"],"prefix":"10.3389","volume":"11","author":[{"given":"I\u00f1aki","family":"Ortiz de Landazuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Egri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Mu\u00f1oz-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Ortiz-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Bola\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"B1","author":"Tay","year":"","journal-title":"The Trinity of COVID-19: Immunity, Inflammation and Intervention. Natural Review Immunology [Internet]."},{"key":"B2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science.","volume":"52","author":"Vabret","year":"","journal-title":"Immunity."},{"key":"B3","author":"Bachanova","year":"2020","journal-title":"Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biology of Blood and Marrow Transplantation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T Cells in refractory B-Cell lymphomas.","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.imlet.2019.10.014","article-title":"CART manufacturing process and reasons for academy-pharma collaboration.","volume":"217","author":"Egri","year":"2020","journal-title":"Immunol Lett."},{"key":"B8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11899-016-0336-z","article-title":"Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you.","volume":"11","author":"Ruella","year":"2016","journal-title":"Curr Hematol Malig Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25 years in the making.","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management.","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy.","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain."},{"key":"B12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2.","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100640","article-title":"Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell therapy.","volume":"40","author":"Bachanova","year":"2020","journal-title":"Blood Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T\u2212cell therapy.","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia.","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy.","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy.","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","article-title":"Year in Review response and resistance.","volume":"19","author":"Brown","year":"2019","journal-title":"Nat Rev Immunol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-Of-Care CAR T-Cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial.","volume":"11","author":"Castella","year":"2020","journal-title":"Front Immunol."},{"key":"B21","article-title":"CART19-BE-01: a multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed\/Refractory malignancies.","author":"Ort\u00edz-Maldonado","year":"","journal-title":"Mol Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1001\/jama.2020.3786","article-title":"Detection of SARS-CoV-2 in different types of clinical specimens.","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1056\/NEJMoa2008457","article-title":"Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility.","volume":"382","author":"Arons","year":"2020","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cgt.2015.5","article-title":"Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.","volume":"22","author":"Levine","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond.","volume":"131","author":"Salter","year":"2018","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11899-019-0498-6","article-title":"Industry\u2019s Giant leap into cellular therapy: catalyzing chimeric antigen receptor T Cell (CAR-T) immunotherapy.","volume":"14","author":"Ittershagen","year":"2019","journal-title":"Curr Hematol Malig Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy.","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel anti-CD19 Chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions.","volume":"12","author":"Castella","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","article-title":"Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.","volume":"18","author":"Mock","year":"2016","journal-title":"Cytotherapy."},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression.","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia.","volume":"38","author":"Frey","year":"2019","journal-title":"J Clin Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia.","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab.","volume":"29","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci USA."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.573179\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T06:21:30Z","timestamp":1602742890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.573179\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2020.573179"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.573179","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"article-number":"573179"}}